

# Annalisa Marinosci

## List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6249603/annalisa-marinosci-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11

papers

22

citations

2

h-index

4

g-index

12

ext. papers

42

ext. citations

8.1

avg, IF

2.1

L-index

#	Paper	IF	Citations
11	Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial. <i>EClinicalMedicine</i> , <b>2021</b> , 42, 101188	11.3	1
10	Prophylaxis for COVID-19: a systematic review. <i>Clinical Microbiology and Infection</i> , <b>2021</b> , 27, 532-537	9.5	12
9	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 4455-4460	3.8	
8	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003421	11.6	7
7	Viral Infections and Cutaneous Drug-Related Eruptions. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 586407	5.6	2
6	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial <b>2020</b> , 17, e1003421		
5	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial <b>2020</b> , 17, e1003421		
4	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial <b>2020</b> , 17, e1003421		
3	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial <b>2020</b> , 17, e1003421		
2	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial <b>2020</b> , 17, e1003421		
1	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial <b>2020</b> , 17, e1003421		